A weekly discussion of all things biotech – breaking news, data, deals, and FDA actions – with a community of biotech industry leaders and experts. Join the live streams hosted by @BiotechCH, @daphnezohar, @bradloncar and @biotech1 on Twitter Spaces every Friday at 12pm ET.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
25%
Guest openness
Selective
Sign up to generate a grounded pitch for Biotech Hangout.
Signup to Generate a PitchA weekly discussion of all things biotech, breaking news, data, deals, and FDA actions, with a community of biotech industry leaders and experts. Join the live streams hosted by @BiotechCH, @daphnezohar, @bradloncar and @biotech1 on Twitter Spaces every Friday at 12pm ET.
Recent episodes include "Episode 199 - October 16, 2026" (16 October 2026, 59 minutes), "Episode 198 - October 2, 2026" (2 October 2026, 60 minutes), and "Episode 197 - September 25, 2026" (25 September 2026, 59 minutes).
Biotech Hangout publishes roughly weekly, with episodes averaging 60 minutes across 149 episodes.
Booking probability for Biotech Hangout is 25%, and the host is rated Selective on guests. Biotech Hangout requires a Pod Score of 83 or higher. Biotech Hangout's contact route on record: verified email.
The strongest fits for Biotech Hangout are Scientific Research & Development. Biotech Hangout has a science audience.
Biotech Hangout is a science show with 149 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Biotech Hangout
On this week’s episode, Graig Suvannavejh, Paul Matteis, Brian Skorney, Yaron Werber, and Jake Becraft opened with a look at the biotech market, with the XBI down roughly 700 basis points in two weeks but still up about...
Biotech Hangout
On this week's episode, Graig Suvannavejh, Sam Fazeli, Eric Schmidt, and Brian Skorney open with a look at the public markets, noting the XBI is up 27% year-to-date but down about 9% since its August high. The co-hosts...
Biotech Hangout
On this week's episode, Sam Fazeli, Yaron Werber, Brian Skorney, and Matt Gline open with the IPO market, noting record average raise sizes even as XBI softens. The group turns to policy, unpacking newly FOIA-disclosed...
Biotech Hangout
On this week's episode, Josh Schimmer, Eric Schmidt, Paul Matteis, and guest Adam Feuerstein open with the OpenAI/Hugging Face AI agent controversy, debating whether calls for AI regulation reflect genuine safety...
Biotech Hangout
On this week's episode, Tess Cameron, Brian Skorney, Paul Matteis, and Yaron Werber open with a look at markets, noting the XBI slipped just over 3% amid concerns about energy prices, inflation, and long-term U.S...
Biotech Hangout
On this week's episode, Daphne Zohar, Eric Schmidt, Sam Fazeli, and Graig Suvannavejh open with a strong week for biotech, partially driven by M&A, noting it's already past 2025's full-year total. The group turns to...
Biotech Hangout
On this week's episode, Chris Garabedian, Graig Suvannavejh, Paul Matteis, and Tess Cameron open with the biotech market. They describe 2026 as strong but discerning, with 19 Nasdaq IPOs this year and generalist...
Biotech Hangout
On this week’s episode, Sam Fazeli, Brian Skorney, Yaron Werber, and Strand Therapeutics CEO Jake Becraft open with the wave of dealmaking and a solid Q2 earnings season, then turn to the reports of the potential...
Biotech Hangout
On this week's episode, Graig Suvannavejh, Tim Opler, Yaron Werber, Paul Matteis, and Brian Skorney kicked off with a review of the market, noting pressure in the XBI despite a longer-term bounce-back from trough...
Biotech Hangout
On this week's episode, Josh Schimmer, Brian Skorney, Eric Schmidt, and Brad Loncar kick off with IPOs and raises, including Scribe's IPO, the first preclinical biotech IPO since the COVID era, which priced in a modest...
Biotech Hangout
On today’s episode, Yaron Werber, John Maraganore, SamFazeli, and Matt Gline open with a discussion of biotech market volatility, withmMatt noting that it often seems driven more by opaque factor dynamics than...
Biotech Hangout
On this week's episode, Sam Fazeli, Josh Schimmer, Eric Schmidt, Paul Matteis, and special guest STAT's Matt Herper open on the market, noting that despite a wobbly day for biotech, the XBI holds strong gains...
Biotech Hangout
On this week’s episode, Josh Schimmer, Eric Schmidt, Tess Cameron, and Sam Fazeli open by noting the XBI’s continued rise, debating whether biotech is getting ahead of itself. The co-hosts call this a “new era” in which...
Biotech Hangout
On this week’s episode, Graig Suvannavejh, Eric Schmidt, Paul Matteis and Financial Times’ Oliver Barnes kicked off with the biotech market, with the XBI in positive territory and 12 biotech IPOs completed so far this...
Biotech Hangout
On this week’s episode, Yaron Werber, Tess Cameron, SamFazeli, and Brian Skorney kick off with a look at markets, noting that while AI remains hot, biotech may be cooling amid anticipated tech IPOs. The co-hosts note...
Biotech Hangout
On this week’s episode, Chris Garabedian, Brian Skorney, Graig Suvannavejh, and special guest Ginkgo Bioworks CEO, Jason Kelly, kick off with a market update, highlighting a continued positive sentiment, citing...
Biotech Hangout
On this week’s episode, Sam Fazeli, Josh Schimmer, Eric Schmidt, and Tess Cameron kickoff with deals, highlighting the up to $15.2B Hengrui–BMS partnership and the broader trend of outsourcing early-stage drug...
Biotech Hangout
On this week’s episode, Josh Schimmer, Paul Matteis, Eric Schmidt, Yaron Werber, and special guest STAT’s Allison DeAngelis open with what they describe as “a bananas week for biotech,” highlighting strong substantial...
Biotech Hangout
On this week’s episode, Eric Schmidt, Matt Gline, Chris Garabedian, Sam Fazeli, and Graig Suvannavejh open with a discussion on biotech public‑market dynamics, noting solid year‑to‑date performance for the XBI. Next...
Biotech Hangout
<p>On today’s episode, Chris Carabedian, Paul Matteis, Tess Cameron, and special guest Adam Feuerstein kick off with a discussion of the public markets, highlighting the XBI’s post‑pandemic highs, Kailera’s IPO pricing...
Recent guests on Biotech Hangout. Study who booked and why before you pitch.
PitchCentric classifies Biotech Hangout under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ